Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.
Also called NCT03373461
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 112 participants
- Sponsor
- Registry
-
NCT03373461 -
2017-000891-27
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Belgium, Brazil, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong SAR China, India, Israel, Japan, Malaysia, Netherlands, Norway, Singapore, South Korea, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03373461. Randomized; double masking; primary purpose treatment. Start 2018-02-07 (actual); primary completion 2020-12-29 (actual). Results posted on 2022-10-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
- Condition
- IgA Nephropathy
- Intervention (Drug)
- LNP023
- Intervention (Other)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03373461- Content hash
f5d8f2d6bfa620cef63bb560143566f5a7ab7b913005229f4d62595ab776b2bf